{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:17:52Z","timestamp":1760242672482,"version":"build-2065373602"},"reference-count":45,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2016,2,2]],"date-time":"2016-02-02T00:00:00Z","timestamp":1454371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Faculty of Medicine, Jagiellonian University Medical College, Leading National Research Center (KNOW) 2012\u20132017","award":["publication costs"],"award-info":[{"award-number":["publication costs"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Angiotensin-converting enzyme inhibitors (ACEI) and statins are widely used in patients with coronary artery disease (CAD). Our aim was to compare changes in glomerular filtration rate (GFR) over time in subjects with stable CAD according to atorvastatin dose and concomitant use of ACEI. We studied 78 men with stable CAD referred for an elective coronary angiography who attained the then-current guideline-recommended target level of low-density lipoproteins (LDL) cholesterol below 2.5 mmol\/L in a routine fasting lipid panel on admission and were receiving atorvastatin at a daily dose of 10\u201340 mg for \u22653 months preceding the index hospitalization. Due to an observational study design, atorvastatin dosage was not intentionally modified for other reasons. GFR was estimated during index hospitalization and at about one year after discharge from our center. Irrespective of ACEI use, a prevention of kidney function loss was observed only in those treated with the highest atorvastatin dose. In 38 subjects on ACEI, both of the higher atorvastatin doses were associated with increasing beneficial effects on GFR changes (mean \u00b1 SEM: \u22124.2 \u00b1 2.4, 1.1 \u00b1 1.6, 5.2 \u00b1 2.4 mL\/min per 1.73 m2 for the 10-mg, 20-mg and 40-mg atorvastatin group, respectively, p = 0.02 by ANOVA; Spearman\u2019s rho = 0.50, p = 0.001 for trend). In sharp contrast, in 40 patients without ACEI, no significant trend effect was observed across increasing atorvastatin dosage (respective GFR changes: \u22121.3 \u00b1 1.0, \u22124.7 \u00b1 2.1, 4.8 \u00b1 3.6 mL\/min per 1.73 m2, p = 0.02 by ANOVA; rho = 0.08, p = 0.6 for trend). The results were substantially unchanged after adjustment for baseline GFR or time-dependent variations of LDL cholesterol. Thus, concomitant ACEI use appears to facilitate the ability of increasing atorvastatin doses to beneficially modulate time-dependent changes in GFR in men with stable CAD.<\/jats:p>","DOI":"10.3390\/ijms17020106","type":"journal-article","created":{"date-parts":[[2016,2,3]],"date-time":"2016-02-03T01:48:18Z","timestamp":1454464098000},"page":"106","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of Atorvastatin Dose and Concomitant Use of Angiotensin-Converting Enzyme Inhibitors on Renal Function Changes over Time in Patients with Stable Coronary Artery Disease: A Prospective Observational Study"],"prefix":"10.3390","volume":"17","author":[{"given":"Ewa","family":"Wieczorek-Surdacka","sequence":"first","affiliation":[{"name":"Department of Nephrology, University Hospital, 31-501 Cracow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta","family":"\u015awierszcz","sequence":"additional","affiliation":[{"name":"Second Department of Cardiology, Jagiellonian University Medical College and University Hospital, 31-501 Cracow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Surdacki","sequence":"additional","affiliation":[{"name":"Second Department of Cardiology, Jagiellonian University Medical College and University Hospital, 31-501 Cracow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2016,2,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/ki.2008.231","article-title":"Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease","volume":"74","author":"Fried","year":"2008","journal-title":"Kidney Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1681\/ASN.2006010012","article-title":"Statins for improving renal outcomes: A meta-analysis","volume":"17","author":"Sandhu","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","article-title":"Benefits and harms of statin therapy for persons with chronic kidney disease: A systematic review and meta-analysis","volume":"157","author":"Palmer","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/eurheartj\/eht065","article-title":"Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: A systematic review and meta-analysis","volume":"34","author":"Hou","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1016\/j.ijcard.2013.08.060","article-title":"A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?","volume":"168","author":"Nikolic","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijcard.2011.06.107","article-title":"A meta-analysis of randomized trials for effects of atorvastatin on renal function in chronic kidney disease","volume":"152","author":"Takagi","year":"2011","journal-title":"Int. J. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sanguankeo, A., Upala, S., Cheungpasitporn, W., Ungprasert, P., and Knight, E.L. (2015). Effects of statins on renal outcome in chronic kidney disease patients: A systematic review and meta-analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0132970"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.amjcard.2014.05.033","article-title":"Meta-analysis of the effect of statins on renal function","volume":"114","author":"Geng","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/eurheartj\/ehl001","article-title":"The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Guidelines on the management of stable angina pectoris: Executive summary","volume":"27","author":"Fox","year":"2006","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.jacc.2007.08.002","article-title":"2007 chronic angina focused update of the ACC\/AHA 2002 guidelines for the management of patients with chronic stable angina: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina","volume":"50","author":"Fraker","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04371206","article-title":"Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The Treating to New Targets (TNT) study","volume":"2","author":"Shepherd","year":"2007","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1464-5491.2010.03139.x","article-title":"Protection against nephropathy in diabetes with atorvastatin (PANDA): A randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin","volume":"28","author":"Rutter","year":"2011","journal-title":"Diabet. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.ajkd.2004.08.040","article-title":"Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on renal function","volume":"45","author":"Epstein","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1042\/CS20130332","article-title":"Statins and the autonomic nervous system","volume":"126","author":"Millar","year":"2014","journal-title":"Clin. Sci. (Lond.)"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.ehj.2004.06.003","article-title":"The Task Force on ACE-inhibitors of the European Society of Cardiology. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease","volume":"25","author":"Swedberg","year":"2004","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/BF00856524","article-title":"The combination of lovastatin and enalapril in a model of progressive renal disease","volume":"8","author":"Brouhard","year":"1994","journal-title":"Pediatr. Nephrol."},{"key":"ref_17","first-page":"1338","article-title":"Effects of delayed treatment with enalapril and\/or lovastatin on the progression of glomerulosclerosis in 5\/6 nephrectomized rats","volume":"8","author":"Lee","year":"1993","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1046\/j.1523-1755.2002.00332.x","article-title":"Effect of combining ACE inhibitor and statin in severe experimental nephropathy","volume":"61","author":"Zoja","year":"2002","journal-title":"Kidney Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"F1203","DOI":"10.1152\/ajprenal.00045.2010","article-title":"Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection","volume":"299","author":"Zoja","year":"2010","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/01.CIR.100.21.2131","article-title":"Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men","volume":"100","author":"Nickenig","year":"1999","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1161\/hq1201.099430","article-title":"Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells","volume":"21","author":"Ichiki","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijcard.2004.04.005","article-title":"Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients","volume":"101","author":"Izzedine","year":"2005","journal-title":"Int. J. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/jcp.2003.012989","article-title":"The effect of statins vs. untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study","volume":"57","author":"Athyros","year":"2004","journal-title":"J. Clin. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0022-5347(01)66010-5","article-title":"Lovastatin has direct renal hemodynamic effects in a rodent model","volume":"156","author":"Stowe","year":"1996","journal-title":"J. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.atherosclerosis.2006.12.020","article-title":"Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia","volume":"196","author":"Ott","year":"2008","journal-title":"Atherosclerosis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3109\/10641963.2012.702835","article-title":"Effects of atorvastatin on systemic and renal nitric oxide in healthy man","volume":"35","author":"Mose","year":"2013","journal-title":"Clin. Exp. Hypertens."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1093\/ndt\/16.11.2152","article-title":"Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease","volume":"16","author":"Kamper","year":"2001","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2337\/diacare.25.7.1211","article-title":"Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: The Diabetes Atorvastatin Lipid Intervention (DALI) Study: A randomized, double-blind, placebo-controlled trial","volume":"25","author":"Bots","year":"2002","journal-title":"Diabetes Care"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.01.004","article-title":"No effects of atorvastatin (10 mg\/d or 80 mg\/d) on prostacyclin, thromboxane and oxidative stress in type 2 diabetes mellitus patients of the DALI study","volume":"94","author":"Tsikas","year":"2015","journal-title":"Pharmacol. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/ki.1995.429","article-title":"Nitric oxide antagonizes the actions of angiotensin II to enhance tubuloglomerular feedback responsiveness","volume":"48","author":"Braam","year":"1995","journal-title":"Kidney Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/apha.12358","article-title":"Oxidative status in the macula densa modulates tubuloglomerular feedback responsiveness in angiotensin II-induced hypertension","volume":"213","author":"Song","year":"2015","journal-title":"Acta. Physiol. (Oxf.)"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/HJH.0b013e32831ef369","article-title":"Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion","volume":"27","author":"Park","year":"2009","journal-title":"J. Hypertens."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"F53","DOI":"10.1152\/ajprenal.00041.2008","article-title":"Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability","volume":"295","author":"Zhou","year":"2008","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/01.CIR.0000138934.28340.ED","article-title":"National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction","volume":"110","author":"Masoudi","year":"2004","journal-title":"Circulation"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1053\/j.ajkd.2008.11.025","article-title":"Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD","volume":"53","author":"Koren","year":"2009","journal-title":"Am. J. Kidney Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/sj.jhh.1001748","article-title":"Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease","volume":"18","author":"Athyros","year":"2004","journal-title":"J. Hum. Hypertens."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.diabres.2013.12.060","article-title":"Effectiveness of combined therapy with angiotensin-converting enzyme inhibitors and statins in reducing mortality in diabetic patients with critical limb ischemia: An observational study","volume":"103","author":"Faglia","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1053\/ajkd.2003.50140","article-title":"A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease","volume":"41","author":"Bianchi","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2010.07.053","article-title":"Effect of atorvastatin on kidney function in chronic kidney disease: A randomised double-blind placebo-controlled trial","volume":"213","author":"Fassett","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/ndt\/gfm943","article-title":"Association between endothelial progenitor cell depletion in blood and mild-to-moderate renal insufficiency in stable angina","volume":"23","author":"Surdacki","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/ndt\/gfp439","article-title":"Synergistic effects of asymmetrical dimethyl-l-arginine accumulation and endothelial progenitor cell deficiency on renal function decline during a 2-year follow-up in stable angina","volume":"25","author":"Surdacki","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_43","unstructured":"Kotz, S., Read, C.B., Balakrishnan, N., and Vidakovic, B. (2006). Encyclopedia of Statistical Science, John Wiley & Sons. Available online: http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/0471667196.ess5050.pub2\/abstract."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S1047-2797(01)00280-0","article-title":"A regression model for longitudinal change in the presence of measurement error","volume":"12","author":"Yanez","year":"2002","journal-title":"Ann. Epidemiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.atherosclerosis.2008.08.016","article-title":"Clinical and subclinical cardiovascular disease and kidney function decline in the elderly","volume":"204","author":"Shlipak","year":"2009","journal-title":"Atherosclerosis"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/2\/106\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:18:38Z","timestamp":1760210318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/2\/106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,2]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2]]}},"alternative-id":["ijms17020106"],"URL":"https:\/\/doi.org\/10.3390\/ijms17020106","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2016,2,2]]}}}